Latest Period
Q4 2025
Security Snapshot
Terns Pharmaceuticals, Inc. - Common Stock (TERN) Institutional Ownership
CUSIP: 880881107
13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026
Institutions Reporting
245
Shares (Excl. Options)
122,594,028
Price
$40.40
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- TERN on Nasdaq
- Shares outstanding
- 105,357,143
- Price per share
- $52.63
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 122,594,028
- Total reported value
- $4,952,935,248
- % of total 13F portfolios
- 0.02%
- Share change
- +32,400,982
- Value change
- +$1,340,517,762
- Number of holders
- 245
- Price from insider filings
- $52.63
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TERN - Terns Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 880881107.
- 245 institutions reported positions in Q4 2025.
- 10 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 245 to 52 between Q4 2025 and Q1 2026.
- Reported value moved from $4,952,935,248 to $209,624,497.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 245 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 880881107?
CUSIP 880881107 identifies TERN - Terns Pharmaceuticals, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 880881107:
Significant Owners of Terns Pharmaceuticals, Inc. - Common Stock (TERN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 8.1% | $20,731,866 | 7,099,954 | Morgan Stanley | 31 Mar 2025 | |||
| BlackRock, Inc. | 6.8% | $16,770,967 | 5,743,482 | BlackRock, Inc. | 31 Dec 2024 | |||
| Adage Capital Management, L.P. | 5.1% | $196,914,000 | 5,550,000 | Adage Capital Management, L.P. | 31 Dec 2025 | |||
| Schonfeld Strategic Advisors LLC | 4.9% | -20% | $12,571,196 | -$2,713,568 | 4,305,204 | -18% | Schonfeld Strategic Advisors LLC | 31 Mar 2025 |
| ORBIMED ADVISORS LLC | 4.8% | $31,842,911 | 4,240,068 | ORBIMED ADVISORS LLC | 03 Nov 2025 | |||
| CITADEL ADVISORS LLC | 4.1% | $10,118,696 | 3,465,307 | Kenneth Griffin | 31 Dec 2024 | |||
| Deep Track Capital, LP | 3% | -62% | $111,762,000 | -$154,160,600 | 3,150,000 | -58% | Deep Track Capital, LP | 31 Dec 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 2.5% | $95,817,820 | 2,700,615 | Vivo Opportunity Fund Holdings, L.P. | 31 Jan 2025 | |||
| Commodore Capital LP | 1.4% | -73% | $52,333,000 | -$149,903,000 | 1,475,000 | -74% | Commodore Capital LP | 31 Dec 2025 |
| Soleus Capital Master Fund, L.P. | 0.2% | -94% | $7,546,951 | -$281,348,949 | 212,710 | -97% | Soleus Capital Master Fund, L.P. | 31 Dec 2025 |
As of 31 Dec 2025, 245 institutional investors reported holding 122,594,028 shares of Terns Pharmaceuticals, Inc. - Common Stock (TERN). This represents 116% of the company’s total 105,357,143 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Terns Pharmaceuticals, Inc. - Common Stock (TERN) together control 76% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.8% | 8,194,218 | +48% | 0.01% | $331,046,406 |
| MORGAN STANLEY | 7.5% | 7,945,608 | +4.7% | 0.02% | $321,002,599 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.3% | 5,550,000 | +41% | 0.34% | $224,220,000 |
| VANGUARD GROUP INC | 5.2% | 5,523,948 | +21% | 0% | $223,167,499 |
| Vivo Capital, LLC | 5.1% | 5,346,928 | -22% | 14% | $216,015,891 |
| Vestal Point Capital, LP | 4.3% | 4,500,000 | 6.7% | $181,800,000 | |
| Avoro Capital Advisors LLC | 4.1% | 4,350,000 | 1.7% | $175,740,000 | |
| JANUS HENDERSON GROUP PLC | 3.2% | 3,379,569 | 0.06% | $136,495,568 | |
| CITADEL ADVISORS LLC | 3% | 3,166,642 | +99% | 0.09% | $127,932,337 |
| Capitolis Liquid Global Markets LLC | 2.9% | 3,045,200 | 0.73% | $123,026,080 | |
| Holocene Advisors, LP | 2.6% | 2,775,493 | 0.24% | $112,129,917 | |
| FRANKLIN RESOURCES INC | 2.6% | 2,731,312 | +114% | 0.03% | $110,345,002 |
| LORD, ABBETT & CO. LLC | 2.6% | 2,712,399 | 0.34% | $109,581,000 | |
| ORBIMED ADVISORS LLC | 2% | 2,153,300 | -72% | 1.9% | $86,993,320 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,096,642 | +22% | 0.01% | $84,723,240 |
| AMERIPRISE FINANCIAL INC | 1.8% | 1,894,381 | 0.02% | $76,533,050 | |
| STATE STREET CORP | 1.7% | 1,775,922 | +11% | 0% | $71,747,249 |
| JPMORGAN CHASE & CO | 1.7% | 1,773,026 | +160% | 0% | $71,630,251 |
| ACORN CAPITAL ADVISORS, LLC | 1.7% | 1,746,264 | -11% | 24% | $70,549,066 |
| Nearwater Capital Markets, Ltd | 1.6% | 1,704,800 | 1.2% | $68,873,920 | |
| Ikarian Capital, LLC | 1.5% | 1,596,378 | +872% | 8.4% | $64,493,671 |
| Pictet Asset Management Holding SA | 1.5% | 1,577,116 | +43% | 0.06% | $63,745,572 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.4% | 1,515,400 | 0.1% | $61,222,160 | |
| Commodore Capital LP | 1.4% | 1,475,000 | -74% | 4% | $59,590,000 |
| TORONTO DOMINION BANK | 1.3% | 1,400,802 | 0.1% | $56,592,401 |
Institutional Holders of Terns Pharmaceuticals, Inc. - Common Stock (TERN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,007,776 | $209,624,497 | -$15,788,134 | $52.72 | 52 |
| 2025 Q4 | 122,594,028 | $4,952,935,248 | +$1,340,517,762 | $40.40 | 245 |
| 2025 Q3 | 88,633,130 | $665,700,838 | +$50,617,366 | $7.51 | 140 |
| 2025 Q2 | 83,108,168 | $309,995,477 | +$2,354,788 | $3.73 | 126 |
| 2025 Q1 | 83,089,113 | $229,386,277 | -$20,904,178 | $2.76 | 134 |
| 2024 Q4 | 86,147,142 | $477,240,000 | +$3,828,882 | $5.54 | 156 |
| 2024 Q3 | 79,491,087 | $663,002,763 | +$119,235,330 | $8.34 | 153 |
| 2024 Q2 | 65,586,958 | $446,681,549 | +$17,184,836 | $6.81 | 124 |
| 2024 Q1 | 63,239,404 | $414,841,261 | -$1,823,851 | $6.56 | 112 |
| 2023 Q4 | 63,584,855 | $412,672,679 | +$14,024,936 | $6.49 | 102 |
| 2023 Q3 | 61,708,912 | $310,396,950 | +$8,574,392 | $5.03 | 92 |
| 2023 Q2 | 57,715,917 | $505,015,397 | +$31,653,493 | $8.75 | 102 |
| 2023 Q1 | 53,226,532 | $630,202,113 | +$46,248,002 | $11.84 | 79 |
| 2022 Q4 | 49,723,793 | $506,193,882 | +$199,453,477 | $10.18 | 65 |
| 2022 Q3 | 30,203,299 | $177,898,000 | +$107,051,162 | $5.89 | 43 |
| 2022 Q2 | 14,707,603 | $36,472,000 | -$6,462,439 | $2.48 | 37 |
| 2022 Q1 | 16,836,162 | $50,004,000 | -$1,388,822 | $2.97 | 43 |
| 2021 Q4 | 16,503,387 | $116,663,000 | -$4,531,477 | $7.07 | 37 |
| 2021 Q3 | 16,724,968 | $174,276,000 | +$979,766 | $10.42 | 33 |
| 2021 Q2 | 16,621,217 | $203,777,000 | -$24,794,385 | $12.26 | 36 |
| 2021 Q1 | 17,905,204 | $393,648,000 | +$393,098,000 | $22.00 | 41 |